Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
63
LZAGF Quote, Financials, Valuation and Earnings
Last price:
$673.60
Seasonality move
:
6.1%
Day range:
$667.58 - $689.14
52-week range:
$560.51 - $755.96
Dividend yield:
0.35%
P/E ratio:
57.13x
P/S ratio:
5.94x
P/B ratio:
4.43x
Volume:
107
Avg. volume:
150
1-year change:
15.27%
Market cap:
$47.3B
Revenue:
$7.5B
EPS (TTM):
$12.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LZAGF
Lonza Group AG
|
-- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$994.8K | -$0.22 | 18.61% | -6.92% | $9.01 |
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$9M | -$1.29 | -89.16% | -180.62% | $81.33 |
|
ONC
BeOne Medicines Ltd.
|
$1.4B | $0.86 | 29.38% | -70.04% | $401.52 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LZAGF
Lonza Group AG
|
$673.60 | -- | $47.3B | 57.13x | $2.38 | 0.35% | 5.94x |
|
ACIU
AC Immune SA
|
$3.03 | $9.01 | $304.8M | -- | $0.00 | 0% | 59.09x |
|
ADXN
Addex Therapeutics Ltd.
|
$7.83 | $30.00 | $9.6M | 0.77x | $0.00 | 0% | 35.81x |
|
CRSP
CRISPR Therapeutics AG
|
$55.86 | $81.33 | $5.3B | -- | $0.00 | 0% | 127.41x |
|
ONC
BeOne Medicines Ltd.
|
$316.05 | $401.52 | $35B | 608.14x | $0.00 | 0% | 7.06x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LZAGF
Lonza Group AG
|
34.86% | 0.314 | -- | 0.87x |
|
ACIU
AC Immune SA
|
6.95% | 3.999 | 2.01% | 1.10x |
|
ADXN
Addex Therapeutics Ltd.
|
0.61% | 2.172 | 0.5% | 1.91x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 3.188 | 3.47% | 16.13x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | 0.334 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LZAGF
Lonza Group AG
|
-- | -- | 5.53% | 8.18% | -- | -- |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$869.9K | -73.49% | -73.84% | -1403.07% | -$687.4K |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
Lonza Group AG vs. Competitors
-
Which has Higher Returns LZAGF or ACIU?
AC Immune SA has a net margin of -- compared to Lonza Group AG's net margin of -1688.87%. Lonza Group AG's return on equity of 8.18% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital LZAGFLonza Group AG-- -- $16.6B ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About LZAGF or ACIU?
Lonza Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $9.01 which suggests that it could grow by 197.75%. Given that AC Immune SA has higher upside potential than Lonza Group AG, analysts believe AC Immune SA is more attractive than Lonza Group AG.
Company Buy Ratings Hold Ratings Sell Ratings LZAGFLonza Group AG0 0 0 ACIUAC Immune SA4 0 0 -
Is LZAGF or ACIU More Risky?
Lonza Group AG has a beta of 1.145, which suggesting that the stock is 14.462% more volatile than S&P 500. In comparison AC Immune SA has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.243%.
-
Which is a Better Dividend Stock LZAGF or ACIU?
Lonza Group AG has a quarterly dividend of $2.38 per share corresponding to a yield of 0.35%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group AG pays 44.76% of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend. Lonza Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGF or ACIU?
Lonza Group AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.2M. Lonza Group AG's net income of -- is lower than AC Immune SA's net income of -$19.8M. Notably, Lonza Group AG's price-to-earnings ratio is 57.13x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group AG is 5.94x versus 59.09x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGFLonza Group AG5.94x 57.13x -- -- ACIUAC Immune SA59.09x -- $1.2M -$19.8M
-
Which has Higher Returns LZAGF or ADXN?
Addex Therapeutics Ltd. has a net margin of -- compared to Lonza Group AG's net margin of -3178.71%. Lonza Group AG's return on equity of 8.18% beat Addex Therapeutics Ltd.'s return on equity of -73.84%.
Company Gross Margin Earnings Per Share Invested Capital LZAGFLonza Group AG-- -- $16.6B ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M -
What do Analysts Say About LZAGF or ADXN?
Lonza Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Addex Therapeutics Ltd. has an analysts' consensus of $30.00 which suggests that it could grow by 283.14%. Given that Addex Therapeutics Ltd. has higher upside potential than Lonza Group AG, analysts believe Addex Therapeutics Ltd. is more attractive than Lonza Group AG.
Company Buy Ratings Hold Ratings Sell Ratings LZAGFLonza Group AG0 0 0 ADXNAddex Therapeutics Ltd.0 0 0 -
Is LZAGF or ADXN More Risky?
Lonza Group AG has a beta of 1.145, which suggesting that the stock is 14.462% more volatile than S&P 500. In comparison Addex Therapeutics Ltd. has a beta of 1.573, suggesting its more volatile than the S&P 500 by 57.32%.
-
Which is a Better Dividend Stock LZAGF or ADXN?
Lonza Group AG has a quarterly dividend of $2.38 per share corresponding to a yield of 0.35%. Addex Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group AG pays 44.76% of its earnings as a dividend. Addex Therapeutics Ltd. pays out -- of its earnings as a dividend. Lonza Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGF or ADXN?
Lonza Group AG quarterly revenues are --, which are smaller than Addex Therapeutics Ltd. quarterly revenues of $62K. Lonza Group AG's net income of -- is lower than Addex Therapeutics Ltd.'s net income of -$2M. Notably, Lonza Group AG's price-to-earnings ratio is 57.13x while Addex Therapeutics Ltd.'s PE ratio is 0.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group AG is 5.94x versus 35.81x for Addex Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGFLonza Group AG5.94x 57.13x -- -- ADXNAddex Therapeutics Ltd.35.81x 0.77x $62K -$2M
-
Which has Higher Returns LZAGF or CRSP?
CRISPR Therapeutics AG has a net margin of -- compared to Lonza Group AG's net margin of -11973.12%. Lonza Group AG's return on equity of 8.18% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital LZAGFLonza Group AG-- -- $16.6B CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About LZAGF or CRSP?
Lonza Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 45.6%. Given that CRISPR Therapeutics AG has higher upside potential than Lonza Group AG, analysts believe CRISPR Therapeutics AG is more attractive than Lonza Group AG.
Company Buy Ratings Hold Ratings Sell Ratings LZAGFLonza Group AG0 0 0 CRSPCRISPR Therapeutics AG12 10 1 -
Is LZAGF or CRSP More Risky?
Lonza Group AG has a beta of 1.145, which suggesting that the stock is 14.462% more volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.738, suggesting its more volatile than the S&P 500 by 73.75%.
-
Which is a Better Dividend Stock LZAGF or CRSP?
Lonza Group AG has a quarterly dividend of $2.38 per share corresponding to a yield of 0.35%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group AG pays 44.76% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Lonza Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGF or CRSP?
Lonza Group AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $889K. Lonza Group AG's net income of -- is lower than CRISPR Therapeutics AG's net income of -$106.4M. Notably, Lonza Group AG's price-to-earnings ratio is 57.13x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group AG is 5.94x versus 127.41x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGFLonza Group AG5.94x 57.13x -- -- CRSPCRISPR Therapeutics AG127.41x -- $889K -$106.4M
-
Which has Higher Returns LZAGF or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Lonza Group AG's net margin of 8.84%. Lonza Group AG's return on equity of 8.18% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital LZAGFLonza Group AG-- -- $16.6B ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About LZAGF or ONC?
Lonza Group AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $401.52 which suggests that it could grow by 27.04%. Given that BeOne Medicines Ltd. has higher upside potential than Lonza Group AG, analysts believe BeOne Medicines Ltd. is more attractive than Lonza Group AG.
Company Buy Ratings Hold Ratings Sell Ratings LZAGFLonza Group AG0 0 0 ONCBeOne Medicines Ltd.18 1 1 -
Is LZAGF or ONC More Risky?
Lonza Group AG has a beta of 1.145, which suggesting that the stock is 14.462% more volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.
-
Which is a Better Dividend Stock LZAGF or ONC?
Lonza Group AG has a quarterly dividend of $2.38 per share corresponding to a yield of 0.35%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lonza Group AG pays 44.76% of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend. Lonza Group AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LZAGF or ONC?
Lonza Group AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Lonza Group AG's net income of -- is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Lonza Group AG's price-to-earnings ratio is 57.13x while BeOne Medicines Ltd.'s PE ratio is 608.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lonza Group AG is 5.94x versus 7.06x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LZAGFLonza Group AG5.94x 57.13x -- -- ONCBeOne Medicines Ltd.7.06x 608.14x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
